Tempus Acquires Personalis for $1.5 Billion, Integrating Residual Cancer Signals into Its AI Precision Medicine Platform

The end of cancer treatment does not mean the risk has disappeared. Surgery or drugs may have made tumors no longer visible on imaging, yet extremely small amounts of tumor DNA may remain in the blood, foreshadowing future recurrence. Tempus AI has agreed to acquire cancer testing company Personalis, aiming to bring this post-treatment gap into its precision oncology platform and create a more complete data chain spanning diagnosis, drug selection, recurrence detection, and long-term follow-up.

The transaction values Personalis at approximately $1.7 billion in total. After excluding Tempus’s current stake, valued at approximately $200 million, the transaction value for the remaining equity is approximately $1.5 billion. The price of $16.25 per share represents a premium of approximately 6% over the closing price on the trading day before the announcement and approximately 28% over the 30-day volume-weighted average price before acquisition speculation emerged in the market. The transaction remains subject to approval by Personalis shareholders and regulators and is expected to close by the end of 2026 or in early 2027.

Personalis’s NeXT Personal is a “tumor-informed” molecular residual disease (MRD) test. It first performs whole-genome sequencing on a patient’s tumor and normal samples to identify the molecular characteristics of the individual tumor, then tracks the corresponding signals in subsequent blood samples. This approach may detect residual disease before it can be identified by conventional imaging, and some results may also reveal newly emerged mutations, helping determine whether changes are present that could be treated with available targeted drugs. However, whether treatment should be adjusted on this basis still depends on the cancer type, clinical evidence, and physician judgment.

The technology also fills out the other side of Tempus’s product portfolio. Tempus’s existing xM MRD uses a “tumor-naive” design that does not require prior tumor mutation information, while Personalis uses data from an individual patient’s tumor to establish tracking markers. The former is less dependent on tissue samples, while the latter currently has greater market adoption. Tempus said it will continue investing in both approaches rather than using the acquisition to completely replace its existing test.

Tempus and Personalis are not unfamiliar parties to a transaction. The two companies have collaborated on promoting MRD testing since 2023 and subsequently expanded their partnership to pharmaceutical research and development and the colorectal cancer market. Personalis reported preliminary revenue of $22.4 million for the second quarter of 2026, delivering 10,384 tests during the quarter, an increase of 33% from the previous quarter. Its gradually expanding commercial capacity and insurance reimbursement coverage are important reasons behind Tempus’s move at this time.

Background

Tempus estimates that the U.S. MRD market opportunity exceeds $20 billion, while penetration remains below 10% for most cancer types. Its bet is not merely on a single blood draw, but on the longitudinal molecular data created as patients undergo repeated testing at different stages of treatment, integrated with medical records and treatment outcomes for use in clinical decision-making and drug development. AI’s role in this framework is primarily to connect and analyze multimodal data; existing reports do not provide new prospective clinical trials demonstrating that AI itself can improve survival or reduce recurrence.

The $1.5 billion therefore buys a potentially fast-growing entry point for testing and data, rather than an established clinical endpoint. What validation is needed for each cancer type, whether positive results can lead to clearly actionable treatment, whether repeat testing can obtain stable reimbursement, and how tumor and normal genome data are protected will still determine whether this acquisition can ultimately progress from growth in testing volume to actual improvements in cancer care.